Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 162 recruiting now early-phase tilt #14 of 28,707 conditions

Colorectal Cancer: early-phase trial registry

162 of 394 indexed Colorectal Cancer trials are currently recruiting, with more weight in Phase 1-2.

Corpus placement: #14 of 28,707 conditions by registered trial count.

394 US clinical trials · 162 currently recruiting · #14 of 28,707 conditions by registered trial count

Colorectal Cancer: 394 US clinical trials tracked, 162 recruiting.

Colorectal Cancer is the subject of 394 registered US clinical trials on ClinicalTrials.gov, 162 of them currently open to new participants. 13 are in Phase 3-4 (later-stage) and 201 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 22 of these trials.

Enrollment posture brief

Registry condition colorectal-cancer

OPEN 162 | RECR 41% | LATE 13 | EARLY 201 | RANK #14 | SPON 22

Nearest open-share peer: Erectile Dysfunction (41% recruiting · 34 trials)

Heart Failure41.1%Colorectal Cancer (this)41%Anxiety40.3%Pain28.1%Asthma18.5%
Open-enrollment share among volume-matched conditions near Colorectal Cancer

Colorectal Cancer lists 162 open slots (41% of 394 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Colorectal Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Colorectal Cancer is recruiting above its size-band peers.

    162 of 394 indexed trials (41.1%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

  2. Sponsorship of Colorectal Cancer trials is spread across many organizations.

    Memorial Sloan Kettering Cancer Center accounts for 22 of 394 trials (5.6%). 222 distinct sponsors appear on at least one study for this condition label.

  3. Typical Colorectal Cancer enrolment sits around 132 participants.

    Median target enrolment is 132 among the 382 trials that report a genuine target (sentinel values excluded). 162 of those (42.4%) plan for fewer than 100 participants.

  4. Colorectal Cancer research is mostly interventional.

    323 interventional and 71 observational studies make up this index (82% interventional). Study type is sponsor-reported on ClinicalTrials.gov.

Phase 1132Phase 269Phase 310Phase 43

Open and recent trials

394 total, page 5 of 8

ACTIVE NOT RECRUITING NA 100 participants

Head to Head Pilot Trial of Mailed Cologuard to Mailed FIT

University of California, San Diego

NCT06173375

ACTIVE NOT RECRUITING Phase 1 100 participants

Phase I Study of Autologous CD8+ and CD4+ Engineered T Cell Receptor T Cells in Subjects With Advanced or Metastatic Solid Tumor

Affini-T Therapeutics

NCT06105021

ACTIVE NOT RECRUITING Phase 1 97 participants

A Safety, Tolerability and Efficacy Study of NC410 Plus Pembrolizumab in Participants with Advanced Unresectable or Metastatic Solid Tumors

NextCure

NCT05572684

ACTIVE NOT RECRUITING Phase 1 96 participants

Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer

Amal Therapeutics

NCT04046445

ACTIVE NOT RECRUITING Phase 1 83 participants

A Study of HFB200603 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors

HiFiBiO Therapeutics

NCT05789069

ACTIVE NOT RECRUITING Phase 1 75 participants

Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer

University of Southern California

NCT03657641

ACTIVE NOT RECRUITING Phase 1 74 participants

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

Novartis Pharmaceuticals

NCT05358249

ACTIVE NOT RECRUITING Phase 1 71 participants

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals

NCT05311618

ACTIVE NOT RECRUITING Phase 1 70 participants

First in Human Study of TORL-3-600 in Participants With Advanced Cancer

TORL Biotherapeutics

NCT05948826

ACTIVE NOT RECRUITING Phase 1 67 participants

Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas

Immunitas Therapeutics

NCT05565417

ACTIVE NOT RECRUITING Phase 2 64 participants

Hepatic Arterial Infusion With Floxuridine and Dexamethasone Combined With Combination Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver

Memorial Sloan Kettering Cancer Center

NCT00492999

ACTIVE NOT RECRUITING NA 60 participants

da Vinci SP® Investigational Device Exemption Study in Colorectal Procedures

Intuitive Surgical

NCT04403022

ACTIVE NOT RECRUITING 49 participants

Colorectal Cancer Awareness, Research and Education and Screening - Rural Expansion, Access and Capacity for Health

H. Lee Moffitt Cancer Center and Research Institute

NCT04464668

ACTIVE NOT RECRUITING Phase 2 48 participants

Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer

University of Colorado, Denver

NCT04963283

ACTIVE NOT RECRUITING Phase 1 44 participants

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation

HUYABIO International

NCT05485974

ACTIVE NOT RECRUITING Phase 1 42 participants

A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations

HUYABIO International

NCT05163028

ACTIVE NOT RECRUITING Phase 1 39 participants

Evaluating Safety and Biomarkers Using DK210 (EGFR) for Locally Advanced or Metastatic EGFR+ Tumors

DEKA Biosciences

NCT05704985

ACTIVE NOT RECRUITING NA 33 participants

Researching the Effect of Exercise on Cancer

Memorial Sloan Kettering Cancer Center

NCT04589468

ACTIVE NOT RECRUITING NA 32 participants

Using an End-of-life Conversation Game to Engage Patients With Cancer in Advance Care Planning: Phase 2

Milton S. Hershey Medical Center

NCT06384417

ACTIVE NOT RECRUITING Phase 1 27 participants

Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

NCT04117087

ACTIVE NOT RECRUITING Phase 1 24 participants

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

M.D. Anderson Cancer Center

NCT05722327

ACTIVE NOT RECRUITING Phase 2 22 participants

Clinical Trial of All-trans-retinoic Acid, Bevacizumab and Atezolizumab in Colorectal Cancer

University of Texas Southwestern Medical Center

NCT05999812

ACTIVE NOT RECRUITING NA 20 participants

Preliminary Investigation of β-hydroxybutyrate Supplementation in Colorectal Cancer Prevention

Abramson Cancer Center at Penn Medicine

NCT05338307

ACTIVE NOT RECRUITING Phase 2 19 participants

Study of Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis From Colorectal, Appendiceal, Small Bowel, Gastric, Cholangiocarcinoma, Breast, Ovarian, or Other Gynecologic Primary Cancer

National Cancer Institute (NCI)

NCT05185947

ACTIVE NOT RECRUITING Phase 1 18 participants

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

AgonOx

NCT05902520

ACTIVE NOT RECRUITING Phase 2 16 participants

Botensilimab and Balstilimab Optimization in Colorectal Cancer

Nicholas DeVito, MD

NCT06268015

ACTIVE NOT RECRUITING Phase 1 16 participants

QUILT-2.025 NANT Neoepitope Yeast Vaccine (YE-NEO-001): Adjuvant Immunotherapy Using a Personalized Neoepitope Yeast-Based Vaccine To Induce T-Cell Responses In Subjects W/ Previously Treated Cancers.

NantBioScience

NCT03552718

ACTIVE NOT RECRUITING Phase 1 12 participants

Study of Cabozantinib Plus TAS102 in mCRC as Salvage Therapy

University of California, Irvine

NCT04868773

ACTIVE NOT RECRUITING NA 12 participants

Abnormal Food Timing and Circadian Dyssynchrony in Alcohol Induced Colon Carcinogenesis

Rush University Medical Center

NCT03955510

ACTIVE NOT RECRUITING Phase 1 6 participants

A Phase 1/2 Trial of TC-510 In Patients With Advanced Mesothelin-Expressing Cancer

TCR2 Therapeutics

NCT05451849

ACTIVE NOT RECRUITING Early Phase 1 2 participants

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer

Roswell Park Cancer Institute

NCT06011772

COMPLETED 44,467 participants

Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode

Guardant Health

NCT04136002

COMPLETED NA 21,860 participants

Computerized and Mailed Reminders in Increasing the Rate of Colorectal Cancer Screening in Adults With an Average Risk for Colorectal Cancer

Harvard Medical School (HMS and HSDM)

NCT00355004

COMPLETED 6,446 participants

Blood and Tissue Sample Collection for Future Colon Cancer Biomarker Studies in Patients Undergoing Colonoscopy

Vanderbilt University

NCT00897403

COMPLETED NA 5,460 participants

Mailed FIT Outreach 2022

Abramson Cancer Center at Penn Medicine

NCT05341622

COMPLETED NA 5,066 participants

Evaluation of an Intervention to Increase Colorectal Cancer Screening in Primary Care Clinics

Centers for Disease Control and Prevention

NCT00737646

COMPLETED NA 3,880 participants

Effect of Patient Portal Messaging Before Mailing Fecal Immunochemical Testing Kit on Colorectal Cancer Screening Rates

University of California, Los Angeles

NCT05115916

COMPLETED Phase 2 2,729 participants

A Telephone-Based Prevention Care Manager in Increasing Screening Rates for Breast Cancer, Cervical Cancer, and Colorectal Cancer in Minority and Low-Income Women

Dartmouth-Hitchcock Medical Center

NCT00376909

COMPLETED NA 2,653 participants

Reminder Modality for CRC Screening

VA Puget Sound Health Care System

NCT05012007

COMPLETED 2,472 participants

Cancer Prevention and Treatment Demonstration for Ethnic and Racial Minorities

M.D. Anderson Cancer Center

NCT00453661

COMPLETED 2,404 participants

A Study of Cologuard™ in an Average Risk Population Assessing a Three Year Test Interval

Exact Sciences Corporation

NCT02419716

COMPLETED NA 2,404 participants

Veteran Primers for CRC Screening

VA Puget Sound Health Care System

NCT04923646

COMPLETED NA 2,241 participants

Helping Women Stay Up-To-Date With Cancer Screening By Using a Prevention Care Manager or Usual Care

Dartmouth-Hitchcock Medical Center

NCT00477646

COMPLETED NA 1,831 participants

Online Study of Colorectal Cancer and Prostate Cancer Screening Decision Making

University of North Carolina, Chapel Hill

NCT01558583

COMPLETED NA 1,826 participants

A Patient Portal Tool, E-assist, for Supporting CRC Screening

UNC Lineberger Comprehensive Cancer Center

NCT02798224

COMPLETED 1,500 participants

Genetic Study of Patients and Families With a History of Colorectal Cancer

Alliance for Clinical Trials in Oncology

NCT00003648

COMPLETED 1,429 participants

PRospective REgistry of Advanced Stage CancER (PREFER) Patients to Assess Prevalence of Actionable Biomarkers and Driver Mutations to Address Disparities in Precision Medicine

Labcorp Corporation of America Holdings

NCT05697198

COMPLETED NA 1,372 participants

The FLU-FOBT Program in Primary Care Settings Where Disparities Persist

University of California, San Francisco

NCT01211379

COMPLETED NA 1,224 participants

Water-aided Colonoscopy vs Air Insufflation Colonoscopy in Colorectal Cancer Screening

Presidio Ospedaliero Santa Barbara

NCT02041507

COMPLETED NA 1,200 participants

Predicting and Addressing Colonoscopy in Safety Net Settings

Kaiser Permanente

NCT03925883

← Previous Page 5 of 8 Next →

Phase Distribution

PhaseTrial count
Phase 1 132
Phase 2 69
Phase 3 10
Phase 4 3

Named interventions

Most-linked intervention names on Colorectal Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Cetuximab Drug
15 trials
Oxaliplatin Drug
14 trials
Bevacizumab Drug
11 trials
irinotecan hydrochloride Drug
9 trials
fluorouracil Drug
9 trials
Irinotecan Drug
9 trials
leucovorin calcium Drug
8 trials
Leucovorin Drug
7 trials

US sites by state

Facility locations filed on Colorectal Cancer trials. A trial with sites in several states counts in each.

California 133 trials
New York 100 trials
Texas 98 trials
Florida 86 trials
Massachusetts 64 trials
Pennsylvania 57 trials
Tennessee 53 trials
Michigan 51 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Colorectal Cancer page

394 registered trials, 162 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Colorectal Cancer condition card totals 394 registered trials; most-linked intervention Cetuximab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.